74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Xenon Pharmaceuticals Inc
Closed
SectorHealthcare
37.98 0.96
Overview
Share price change
24h
Min
36.66
Max
38.21
Income | -2.9M -66M |
|---|---|
EPS | -0.84 |
Employees | 316 |
EBITDA | -3.8M -77M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +43.98% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -238M 2.7B |
|---|---|
Previous open | 37.02 |
Previous close | 37.98 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Xenon Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Xenon Pharmaceuticals Inc Forecast
Price Target
By TipRanks
43.98% upside
12 Months Forecast
Average 55 USD 43.98%
High 65 USD
Low 42 USD
Based on 13 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
